Project/Area Number |
25462165
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Cardiovascular surgery
|
Research Institution | Yokohama City University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
MASUDA Munetaka 横浜市立大学, 医学系研究科, 教授 (10190365)
IMOTO Kiyotaka 横浜市立大学, 市民総合医療センター, 教授 (40203335)
UCHIDA Keiji 横浜市立大学, 市民総合医療センター, 准教授 (50275062)
YOKOYAMA Utako 横浜市立大学, 医学部, 准教授 (70404994)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | オーダーメイド医療 / 大動脈瘤 / 弾性繊維形成 |
Outline of Final Research Achievements |
The purpose of the study is to produce the first drug which is able to inhibit aneurysmal formation. In human tissue samples obtained from AAA(abdominal aortic aneurysm) sugery, we found that EP4 expression and elastic fiber degradation were both enhanced in the aneurismal area relative to that in the normal area. When human AAA smooth muscle cells (hAAASMCs) were stimulated by PGE, antagonist EP4 , or PGE+antagonist EP4, IL-6, MMP or other protease were detected from hAAASMCs, which suggested signal of PGE-EP4 might play a role to aneurysmal formation. Value of a protein which has been found in blood was decreased after endovascular therapy and reduced size of AAA in AAA patients. The protein might be one of biomarker of aortic aneurysm. We already applied for a patent of the biomarker.
|